Diabetic medications in pregnancy

Current Diabetes Reviews
James Young, Aresh Anwar

Abstract

All forms of diabetes are increasing in prevalence, but with the advent of the obesity epidemic, we now face the prospect of an increasing number of women conceiving whilst taking traditional oral antidiabetic agents (OADs). This is also further complicated by the availability of new incretin-based therapies, the dipeptidylpeptidase-4 (DPP-IV) inhibitors and glucagon-like-1 receptor (GLP-1R) analogues. Original concerns regarding the use of such OADs have meant that diet control and insulin has been the mainstay of treatment for hyperglycaemia during pregnancy. However, recent NICE guidelines have suggested a role for oral antidiabetic agents. Safety is of paramount concern, especially in pregnancy, and this review will discuss the evidence to date.

Citations

Feb 18, 2014·Diabetic Medicine : a Journal of the British Diabetic Association·R I G Holt, K D Lambert
Aug 14, 2018·The Cochrane Database of Systematic Reviews·Ruth MartisJulie Brown
Dec 8, 2011·Arquivos brasileiros de endocrinologia e metabologia·Letícia Schwerz WeinertAngela Jacob Reichelt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.